

CERTIFICATE OF EXPRESS MAIL UNDER 37 CFR 1.10

"Express Mail" Label No. EQ478121427US Date August 2, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" Post Office to addressees" on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(signature)

Robin Ustanik

(typed/printed name)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rodriguez, et al.

Application No.: 10/802,273

Filing Date: March 17, 2004

Title: Prevention Of Ovarian Cancer By
Administration Of Products That Induce
Biologic Effects In The Ovarian Epithelium

Examiner: Leslie A. Royds

Group Art Unit: 1614

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

Pursuant to 37 C.F.R. 1.97 and 1.98, and in compliance with 37 C.F.R. 1.56, the Office's attention is directed to the references listed on the attached PTO-1449 forms. A copy of each of the listed documents is enclosed.

The undersigned believes that this Statement is being filed before the mailing of the first Office Action after the filing of the request for continued examination under §1.114, and that no fee is due pursuant to 37 C.F.R. §1.97(b)(4). In the event a first Office Action on the merits was mailed before the filing of this Statement, the Office is authorized to treat this submission as

though made pursuant to 37 C.F.R. §1.97(c) and to charge the fees set forth in 37 C.F.R.
§1.17(p) to Deposit Account No. 10-0460.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Ray N. Nimrod', written over a horizontal line.

Raymond N. Nimrod
Registration No. 31,987

Jenner & Block LLP
One IBM Plaza
Chicago, IL 60611
Ph. (312) 927-5833
Fax (312) 923-8406

Date: August 2, 2006



08-04-06

24 /FW

PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/802,273
	Filing Date	March 17, 2004
	First Named Inventor	Gustavo C. Rodriguez
	Art Unit	1614
	Examiner Name	Leslie A. Royds
Total Number of Pages in This Submission	Attorney Docket Number	31162B


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. 105 References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	2. Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Jenner & Block		
Signature			
Printed name	Raymond N. Nimrod		
Date	August 2, 2006	Reg. No.	31,987

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Robin L. Ustanik	Date	August 2, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 8**Complete if Known**

Application Number	10/802,273
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	31162B

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 3,957,982	05-18-1976	Lachnit-Fixson et al.	
		US- 3,969,502	07-13-1976	Lachnit-Fixson	
		US- 4,390,531	06-28-1983	Edgren	
		US- 4,530,839	07-23-1985	Pasquale	
		US- 4,544,554	10-01-1985	Pasquale	
		US- 4,616,006	10-07-1986	Pasquale	
		US- 4,621,079	11-04-1986	Lachnit-Fixson et al.	
		US- 4,628,051	12-09-1986	Pasquale	
		US- 4,760,053	07-26-1988	Labrie	
		US- 4,817,819	04-04-1989	Kelly	
		US- 4,833,125	05-23-1989	Neer	
		US- 4,855,305	08-08-1989	Cohen	
		US- 4,906,169	03-06-1990	Chien	
		US- 4,921,843	05-01-1990	Pasquale	
		US- 4,962,098	10-09-1990	Boissonneault	
		US- 5,108,995	04-28-1992	Casper	
		US- 5,256,421	10-26-1993	Casper	
		US- 5,262,408	11-16-1993	Bergink	
		US- 5,280,023	01-18-1994	Ehrlich et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 0 253 607 A1	01-20-1988	Upton		
		EP 0 253 607 B1	01-20-1988	Upton		
		EP 0 628 312 B1	12-14-1994	Wablat		
		WO 95/26730 A1	10-12-1995	Schering		
		WO 97/11680	04-03-1997	Elliesen		
		WO 98/10771 A1	03-19-1998	Rodriguez		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

8

Complete if Known

Application Number	10/802,273
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	31162B

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,314,694	05-24-1994	Gale et al.	
		US- 5,382,573	01-17-1995	Casper	
		US- 5,416,091	05-16-1995	King	
		US- 5,418,228	05-23-1995	Bennink	
		US- 5,422,119	06-06-1995	Casper	
		US- 5,461,041	10-24-1995	Bergink et al.	
		US- 5,468,736	11-21-1995	Hodgen	
		US- 5,552,394	09-03-1996	Hodgen	
		US- 5,583,129	12-10-1996	Spona et al.	
		US- 5,595,970	01-21-1997	Garfield et al.	
		US- 5,620,705	04-15-1997	Dong et al.	
		US- 5,633,011	05-27-1997	Dong et al.	
		US- 5,747,480	05-05-1998	Gast	
		US- 5,780,497	07-14-1998	Miller et al.	
		US- 5,842,476	12-01-1998	Wright et al.	
		US- 5,855,906	01-05-1999	McClay	
		US- 5,858,405	01-12-1999	Gast	
		US- 5,888,543	03-30-1999	Gast	
		US- 5,891,868	04-06-1999	Cummings et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 98/56389 A1	12-17-1998	Rodriguez		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of 8

Complete if Known

Application Number	10/802,273
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	31162B

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,898,038	04-27-1999	Yallampalli et al.	
		US- 5,922,349	07-13-1999	Elliesen et al.	
		US- 6,028,064	02-22-2000	Rodriguez et al.	
		US- 6,034,074	03-07-2000	Rodriguez et al.	
		US- 6,310,054	10-30-2001	Rodriguez et al.	
		US- 6,319,911	11-20-2001	Rodriguez et al.	
		US- 6,407,082	06-18-2002	Rodriguez et al.	
		US- 6,444,658	09-03-2002	Rodriguez et al.	
		US- 6,511,970	01-28-2003	Rodriguez et al.	
		US- 6,765,002	07-20-2004	Rodriguez et al.	
		US- 6,977,250	12-20-2005	Rodriguez et al.	
		US- 7,053,074	05-30-06	Rodriguez et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 4	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ARCHER, et al., A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 mg and Ethinyl Estradiol 20 mg, Contraception, (1997) 55:139-144	
		BAST, et al., Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, Chapter 321, 13th Ed., Isselbacher et al., (Eds.) pp. 1853-1858, McGraw-Hill, New York	
		BU, et al., Progesterone Induces Apoptosis and Up-Regulation of p53 Expression in Human Ovarian Carcinoma Cell Lines, Amer. Cancer Society, 1997, 79:1944-1950, China	
		CASAGRANDE, et al., "Incessant Ovulation" and Ovarian Cancer, The Lancet, July 28, 1979, pp. 170-172, Los Angeles, California	
		EVANGELOU, et al., Down-regulation of Transforming Growth Factor B receptors by androgen in ovarian cancer cells, Cancer Research, 2000, 60:929-935	
		FRANCESCHI, et al., Pooled Analysis of 3 European Case-Control Studies of Epithelial Ovarian Cancer: III. Oral Contraceptive Use, Int. J. Cancer, 1991, 49:61-65, Wiley-Liss	
		GREENE, et al., The Epidemiology of Ovarian Cancer, Seminars in Oncology, September 1984, pp. 209-225, Vol. 11, No. 3, USA	
		GRIMES, et al., Primary Prevention of Gynecologic Cancers, Am. J. Obstet. Gynecol., January 1995, pp. 227-235, San Francisco, California	
		GROSS, et al., The Estimated Effect of Oral Contraceptive Use on the Cumulative Risk of Epithelial Ovarian Cancer, OCs and Ovarian Cancer, 1994 pp. 419-424, Vol. 83, No. 3 USA	
		HAMMOND, Climacteric, Danforth's Obstetrics and Gynecology, 1994, pp. 771-790, Chapter 42, 7th Ed., Philadelphia	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 5 of 8	Attorney Docket Number	31162B	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HICKEY, et al., Metabolic and Endocrinologic Effects of Steroidal Contaception, J. Sciarra Editor, 1996, pp. 1-14, Vol. 6, Chapter 24, Lippincott, Philadelphia	
		JORDAN, The Estrogenic Activity of Synthetic Progestins Used in Oral Contraceptives, Cancer, 1993, Vol. 71, No. 4, pp. 1501-1505.	
		LEE, The Reduction in Risk of Ovarian Cancer Associated with Oral Contraceptive Use, 1987, New Engl. J. Med., 316:650-655	
		LEFKOWITZ, et al., Sunlight, Vitamin D, and Ovarian Cancer Mortality Rates in US Women, International Journal of Epidemiology, 1994, pp. 1133-1136, Vol 23, No 6, Great Britian	
		LIANG, et al., Risk of Breast, Uterine Corpus, and Ovarian Cancer in Women Receiving Medroxyprogesterone Injections, JAMA, 1983, pp. 2909-2912, Vol. 249, No. 21, USA	
		LINGEMAN, Etiology of Cancer of the Human Ovary: A Review, The Journal of the National Cancer Institute, December 1974, pp. 1603-1618, Vol. 53, No. 6	
		LOCKER, et al. Hormonal Therapy of breast cancer, Cancer Treatment Reviews, 1998, Vol. 24, pp. 221-240, W.B. Saunders Company Ltd.	
		LOCKSHIN, et al., The Biology of Cell Death and Its Relationship to Aging, Cellular Aging and Cell Death, 1996, pp. 167-180, Wiley-Liss Inc.	
		LOWE, et al., p53-Dependent Apoptosis in Tumor Progression and in Cancer Therapy, Cellular Aging and Cell Death, 1996, pp. 209-234, Wiley-Liss, Inc.	
		LUNDGREN, et al., Progestins in Breast Cancer treatment, ACTA Oncologica, 1992, Vol. 31, No. 7, pp. 709-722, Trondheim, Norway.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 6	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MAGOFFIN, et al., Estradoil-17B, insulin like growth factor-1, and lutienizing hormone inhibit secretion of transforming growth factor B by rat ovarian theca-interstitial	
		(continued from above) cells, Biology of Reproduction, 1995, 53, pp. 627-635	
		MUSS, et al., High-dose progestin therapy for metastatic breast cancer, Annals of Oncology, 1992, pp. S15-S20, Vol. 3, Netherlands	
		MUSS, Tamoxifen Versus High-Dose oral medroxyprogesterone Acetate as intital endocrine therapy for patients with metastatic breast cancer: A Peidmont,	
		(continued from above) Oncology Associate Study, Journal of Clinical Oncology, 1994, pp. 1630-1638, Vol. 12, No. 8	
		MUTCH, et al., Biology of Epithelial Ovarian Cancer, Clinical Obstetrics and Gynecology, 1994, pp. 406-422, Vol. 37, No. 2, L.B. Lippincott Co.	
		PFLEIDERER, The Problems of Prophylactic Chemotherapy, Second-look Surgery, and Maintenance of Remission in Therapy of Ovarian Cancer, Geburtshilfe und Frauenheilkunde,	
		(continued from above) 1976, pp. 132-139, Vol. 36, Germany	
		RAVIN, et al., Preformulation, Remington's Pharmaceutical Sciences, 1990, pp. 1435-1712, Chapters 75-92, Mack Publishing Co., Easton, PA	
		RODRIGUEZ, et al., Estrogen Replacement Therapy and Fatal Ovarian Cancer, American Journal of Epidemiology, 1995, pp. 828-835, Vol. 141, No. 9, USA	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 7	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROSENBERG, et al., A Case-Control Study of Oral Contraceptive Use and Invasive Epithelial Ovarian Cancer, 1994, pp. 654-661, Vol. 139, No. 7, USA	
		ROSENBLATT, et al., High-dose and Low-dose Combined Oral Contraceptives: Protection Against Epithelial Ovarian Cancer and the Length of the Protective Effect,	
		(continued from above) Eur. J. Cancer, 1992, pp. 1872-1876, Vol. 28A, No. 11, Great Britian	
		ROSSING, et al., Ovarian Tumors in a Cohert of Infertile Women, The New England Journal of Medicine, 1994, pp. 771-776, Vol. 331, No. 12	
		RUDEL, Pharmacology of Contraceptive Steriods, Gynecology and Obstetrics, 1996, pp. 1871-1876, Vol. 6, Chapter 19	
		SCOTT, How to Induce Ovarian Cancer: And How Not To, British Medical Journal, September 29, 1984, pp. 781, 784, Vol. 289, Leeds	
		SPEROFF, et al., Steroid Contraception, Clinical Gynecologic Endocrinology and Infertility, 1989, Chapter 15, 4th Ed., pp. 461-498	
		STANFORD, et al. Epithelial Ovarian Cancer and Combined Oral Contraceptives, International Journal of Epidermiology, 1989, pp. 538-545, Vol. 18, No. 3, Great Britian	
		STANFORD, et al., Depot-Medroxyprogesterone Acetate (DMPA) and Risk of Epithelial Ovarian Cancer, Int. J. Cancer, 1991, pp. 191-195, Vol. 49, Wiley-Liss, Inc.	
		VOGEL, et al. Hormonal Approaches to Breast Cancer Treatment and Prevention: An Overview, Seminars in Oncology, 1996, pp. 2-9, Vol. 23, No. 4, Supp. 9	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
		Attorney Docket Number	31162B
Sheet	8	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VOGEL, Update on the current use of hormonal as therapy in advanced breast cancer, use of homonals in advanced breast cancer, Anti-Cancer Drugs, 2003, 14:265-273	
		WINGO, et al., Cancer Statistics 1995, A Cancer Journal for Clinicians, 1995, p. 30, Vol. 45, No. 1	
		WHITEMORE, Characteristics Relating to Ovarian Cancer Risk: Implications for Prevention and Detection, Gynecologic Oncology, 1994, pp. S15-S19, Vol. 55, USA	
		WHITEMORE, et al., Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies, Am. J. Epidem, 1992, pp. 1212-1220, Vol. 136, No 10	
		WU, et al., Personal and Environmental Characteristics Related to Epithelial Ovarian Cancer, Am. J. Epidem., 1988, pp. 1216-1227, Vol. 128, No. 6, USA	
		YOUNG, et al. Gynecologic Malignancies, Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, 13th Ed. pp. 1605-608	
		U.S. Patent Application Ser. No. 10/802,427 filed on March 17, 2004 (Inventor: Rodriguez, et al.)	
		Physicians' Desk Reference, 1996, pp. 1871-1876	
		CARLSTROM et al., Gynecologic and Obstetric Investigation, (1978), Vol. 9, No. 6, pp. 304-11 (Medine Abstract Only)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 8	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VOGEL, Update on the current use of hormonal as therapy in advanced breast cancer, use of homonals in advanced breast cancer, Anti-Cancer Drugs, 2003, 14:265-273	
		WINGO, et al., Cancer Statistics 1995, A Cancer Journal for Clinicians, 1995, p. 30, Vol. 45, No. 1	
		WHITTEMORE, Characteristics Relating to Ovarian Cancer Risk: Implications for Prevention and Detection, Gynecologic Oncology, 1994, pp. S15-S19, Vol. 55, USA	
		WHITTEMORE, et al., Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies, Am. J. Epidem, 1992, pp. 1212-1220, Vol. 136, No 10	
		WU, et al., Personal and Environmental Characteristics Related to Epithelial Ovarian Cancer, Am. J. Epidem., 1988, pp. 1216-1227, Vol. 128, No. 6, USA	
		YOUNG, et al. Gynecologic Malignancies, Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, 13th Ed. pp. 1605-608	
		U.S. Patent Application Ser. No. 10/802,427 filed on March 17, 2004 (Inventor: Rodriguez, et al.)	
		Physicians' Desk Reference, 1996, pp. 1871-1876	
		CARLSTROM et al., Gynecologic and Obstetric Investigation, (1978), Vol. 9, No. 6, pp. 304-11 (Medine Abstract Only)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.